The Trump administration has drawn a direct line from federal drug enforcement to the largely unregulated intoxicating hemp market - and the industry is taking notice. The 2026 National Drug Control Strategy, prepared by the White House Office of National Drug Control Policy, positions delta-8 THC, delta-10 THC, THC-O, THCP, and related analogues as targets for enforcement action, citing what it describes as a "new legal authority" created when the president signed legislation closing a hemp loophole last year. For retailers, distributors, and brands that built product lines around these derivatives, the message is unambiguous: the federal government intends to treat these substances as illicit, not merely unclassified.
What the ONDCP Strategy Actually Says - and Why the Framing Matters
The ONDCP's biennial strategy report is not legislation. It doesn't create new law on its own. But it does set enforcement priorities across federal agencies, and the specific language it uses here carries weight. "Enforcement will focus on substances falling outside regulatory frameworks or being sold illegally," the report states, adding that "shutting down these domestic sources of harmful substances is crucial to degrading the overall availability of illicit drugs within our communities."
That language deliberately groups intoxicating hemp derivatives with the illicit drug supply - a meaningful rhetorical and legal move. The administration's claim of "new legal authority" stems from the Farm Bill amendment that closed what critics had long called the hemp loophole: a gap in the 2018 Farm Bill that allowed hemp-derived cannabinoids to be sold as consumer products as long as the final product contained no more than 0.3% delta-9 THC by dry weight. Chemists and manufacturers used that gap to produce concentrated forms of other psychoactive cannabinoids - delta-8 in particular - that weren't explicitly scheduled under federal law.
The 2026 Farm Bill, which passed the House with the intoxicating hemp ban intact despite industry lobbying efforts, keeps that prohibition in place. Whether the Senate follows suit, and how quickly any ban could be implemented in practice, remains open. But the ONDCP report signals the executive branch isn't waiting for a final legislative resolution to begin building an enforcement posture.
Retail and Distribution Exposure Is Significant
Here's the operational reality for anyone currently selling delta-8 or similar products: the federal government has now characterized those products as falling "outside regulatory frameworks" in a formal policy document. That's a different risk profile than simply operating in a gray area.
Hemp-derived intoxicating products have found shelf space in convenience stores, vape shops, gas stations, and standalone hemp retailers - businesses that are not licensed cannabis operators and have no compliance infrastructure designed around Schedule I enforcement. They don't have seed-to-sale tracking systems, DEA registration requirements, or compliant packaging protocols built for controlled substances. That's precisely what made the category commercially attractive to non-cannabis retailers: lower barriers to entry, no state cannabis license required, and minimal regulatory overhead.
That structural informality is now the exposure. If federal enforcement treats delta-8 and analogues as Schedule I chemicals - which the ONDCP strategy implies - then distribution, retail sale, and possession with intent to distribute could carry serious criminal liability for businesses that have never operated within a licensed cannabis compliance framework. And unlike state-licensed dispensaries, these retailers have no DEA registration pathway to claim good-faith compliance.
The DEA Registration Parallel - and Its Complications
The hemp enforcement story doesn't exist in isolation. May's most-read coverage from Cannabis Business Times reveals a regulatory environment in motion on multiple fronts simultaneously. While the ONDCP targets intoxicating hemp derivatives on one side of the market, state-licensed medical cannabis operators are grappling with their own federal compliance questions on the other - specifically, whether and how to register with the DEA under the Schedule III rescheduling framework initiated by Acting Attorney General Todd Blanche's order.
The parallel is instructive. A Congressional Research Service analysis found that medical cannabis businesses handling Schedule III products "will need to register with DEA in order to do so lawfully." That sounds straightforward. It isn't. Former federal prosecutor Julie Werner-Simon and former IRS lawyer Jonathan Kalinski have warned operators that registering cedes authority to federal regulators - including DEA's broad discretion to deny applications on public interest grounds. The DEA, for its part, told Cannabis Business Times that a red-flag question on the application asking businesses to essentially admit prior drug trafficking is "not intended … as a categorical barrier," but is meant to support a "complete and fair evaluation."
What does any of this have to do with intoxicating hemp? The through-line is regulatory standing. Licensed cannabis businesses have a potential pathway into federal compliance - however fraught - because they already operate within state-regulated frameworks. Unregistered hemp retailers selling psychoactive derivatives have no such pathway. If enforcement moves forward as the ONDCP strategy implies, they're not being asked to register or comply; they're being told to stop.
What Operators Should Watch Now
The enforcement timeline is not yet defined. The ONDCP strategy sets direction; it doesn't specify when, how, or which agencies will act first. But the direction is clear enough that businesses in the intoxicating hemp space - and the licensed cannabis operators who compete with them - should be paying close attention to a few pressure points.
- Farm Bill final passage: The House-passed 2026 Farm Bill retains the intoxicating hemp ban, but the Senate has not yet acted. Any amendment process could change the ban's scope, create carve-outs, or delay implementation. Industry stakeholders have reportedly continued lobbying for fixes, though no resolution is guaranteed.
- DEA scheduling determinations: The ONDCP report states that delta-8, delta-10, THC-O, THCP, and other analogues will be treated as Schedule I chemicals. Formal DEA scheduling action would create clearer enforcement authority and make violations prosecutable under the Controlled Substances Act.
- State-level divergence: Several states have moved to regulate intoxicating hemp products through their existing cannabis frameworks or standalone statutes. In those states, licensed operators may have some compliance cover. In states without such frameworks, the gap between federal enforcement intent and local enforcement capacity will be a live variable.
- Competitive dynamics for licensed dispensaries: Licensed adult-use and medical cannabis retailers have competed for years against unregulated intoxicating hemp products - sometimes sold at lower prices and without the compliance overhead that state-licensed businesses carry. If federal enforcement meaningfully narrows the intoxicating hemp market, that competitive dynamic shifts. That's not a reason for operators to cheer prematurely; the transition will create market uncertainty and potential consumer confusion. But it is a business variable worth modeling.
The plain-English version of all this: the federal government has decided the intoxicating hemp gray market is a drug enforcement problem, not a labeling problem or an agricultural classification debate. Businesses still operating in that space without a clear legal framework should take that signal seriously - and consult legal counsel before the enforcement architecture becomes more concrete.
